Takeda forms “first of its kind” developmental partnership with CRO
pharmafile | September 13, 2016 | News story | Manufacturing and Production, Research and Development | PRA Health Services, Takeda, partnership
Takeda and PRA Health Services have announced a new partnership that will see the Japanese pharma giant transfer 300 staffers to the clinical research firm in order to deliver on development of its pipeline.
This development follows a $725 million reorganisation effort for Takeda announced in late July. The partnership is designed to provide a flexible operating model giving US and European employees the chance to take new roles at the CRO, a “first of its kind in the CRO industry” according to PRA CEO Colin Shannon.
“This partnership is an exciting opportunity for PRA and represents a significant milestone and transformational business opportunity for us,” said Shannon. “This is the first time that a pharmaceutical company and a clinical research organisation (CRO) have come together to create such a comprehensive business and operational strategy.”
The deal hopes to stimulate research and facilitate the development of new medicines as the CRO takes responsibility for a full pipeline of studies from Phase I to Phase IV and provides regulatory, pharmacovigilance and other operational services for both developmental and marketed product portfolios.
“This partnership is a fundamental part of Takeda’s R&D transformation and represents a truly innovative approach to clinical development, unprecedented in our industry,” added Andy Plump, director and chief medical and scientific officer at Takeda. “PRA has a reputation for providing tailored sourcing solutions. We believe PRA will be an ideal partner as we focus, deliver and advance our current and future pipeline.”
Matt Fellows
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
